Anna C. Pavlick - Researcher Profile

Publications

3 shown

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

Antoni Ribas , Igor Puzanov , Reinhard Dummer +33 more

2015 The Lancet Oncology 1528 citations

Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma

Michael A. Postow , Jason Chesney , Anna C. Pavlick +18 more

The objective-response rate and the progression-free survival among patients with advanced melanoma who had not previously received treatment were significantly greater with niv...

2015 New England Journal of Medicine 2716 citations

A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma

Reinhard Dummer , Adil Daud , Igor Puzanov +18 more

2 and 10 mg/kg Q3W, respectively, over control (P<0.00001 for both comparisons). The 6-month PFS rate was 34% (95% CI 27%-41%) and 38% (95% CI 31%45%) for pembrolizumab 2 and 10...

2015 Journal of Translational Medicine 94 citations

Frequent Co-Authors

Researcher Info

h-index: 3
Publications: 3
Citations: 4,338
Institution: New York University

External Links

ORCID Profile Google Scholar

Identifiers

ORCID: 0000-0001-7088-0742

Impact Metrics

h-index 3

h-index: Number of publications with at least h citations each.